Trial Evaluating Lisocabtagene Maraleucel for Relapsed/Refractory CLL Meets Endpoint
Lisocabtagene maraleucel is a CD19-directed genetically modified autologous T cell immunotherapy.
Diagnosis & Disease Information
Pemazyre Approved for Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement
The approval was based on data from the phase 2 FIGHT-203 study, which included 28 patients with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement.
Omidubicel Gets Priority Review for Patients in Need of Stem Cell Transplant
Omidubicel is a first-in-class, advanced NAM (nicotinamide)-enabled stem cell therapy candidate.
COVID-19 Booster May Spur Seroconversion in Blood Cancer Patients
Among nonresponders to initial COVID-19 vaccination, seroconversion occurred in 56 percent following booster dose
May 2022: Drug Pipeline Updates
Stay up-to-date on the latest drugs in development.
Kymriah Gets Accelerated Approval for Relapsed/Refractory Follicular Lymphoma
The accelerated approval for Kymriah was based on data from the phase 2 ELARA trial.
Tibsovo Approval Expanded for Newly Diagnosed IDH1-Mutated AML
The approval was based on data from the phase 3 AGILE trial.
Gene Editing Therapy Wins Fast Track Designation for Sickle Cell Disease
GPH101 is an investigational gene-edited autologous hematopoietic stem cell therapy designed to correct the mutation in the beta-globin gene and potentially curing the disease.
Gender Pay Gap Affects Most Medical Specialties, Persists Over Time
Women in academic medicine typically have lower starting salaries than men, and this disparity remains after 10 years on the job.
